StocktwitsEarnings
$FULC Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.14 up 54.84% YoY
• Fulcrum Therapeutics expects the Merger to close in fourth quarter 2026 and expects to declare a $275M aggregate cash dividend to pre-Merger stockholders, subject to adjustment under the Merger Agreement.
